CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy

BACKGROUND: Neoadjuvant chemotherapy (NAC) is the standard therapeutic strategy for triple-negative breast cancer (TNBC). TNBC patients with residual disease after NAC have a significantly worse survival than those with pathological complete response (pCR); however, there is no apparent prognostic f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer
Main Authors: Tokunaga, Eriko, Fujita, Aya, Takizawa, Katsumi, Baba, Kimiko, Akiyoshi, Sayuri, Nakamura, Yoshiaki, Ijichi, Hideki, Masuda, Takanobu, Koga, Chinami, Tajiri, Wakako, Ohno, Shinji, Taguchi, Kenichi, Ishida, Mayumi
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Japan 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6314992/
https://ncbi.nlm.nih.gov/pubmed/29971631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-018-0888-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados